February 2017
J7207 replaces J7199 when billing for Adynovate® (antihemophilic factor recombinant) PEGylated
The Centers for Medicare & Medicaid Services has established a permanent procedure code for Adynovate® (antihemophilic factor recombinant) PEGylated, effective Jan. 1, 2017.
All services from Nov. 13, 2015, through Dec. 31, 2016, will continue to be reported with code J7199. All services performed on and after Jan. 1, 2017, must be reported with J7207.
Adynovate (antihemophilic factor recombinant) PEGylated continues to be covered for the FDA-approved indications as establisted on Nov. 13, 2015.
Pharmacy doesn’t require preauthorization of this drug.
|